NCT00811213

Brief Summary

The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep. This study will investigate Obstructive Sleep Apnea (OSA) and a automatically Adjusting Positive Airway Pressure (APAP) device with new technology called SensAwake™. This requires experimental confirmation in a randomised controlled trial. Double-blind randomised crossover trial comparing WASO on standard APAP with WASO using APAP modified by the addition of the SensAwake™ modification on consecutive nights in participants with moderate-to-severe OSA. A total number of 45 participants will be recruited from an OSA population, aged 18-65. Participants will consist of male and female patients diagnosed with moderate-severe OSA (Apnea Hypopnea Index (AHI) greater than or equal to 15 per hour. Eligible participants, according to the protocol approved by the HREC, providing written informed consent will be enrolled into the study. Patients will be enrolled sequentially according to the randomisation list. Patients will be randomised to APAP or APAP with the addition of the SensAwake™ modification. The investigator and study staff will be blinded to the treatment of any participant.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Oct 2008

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

December 16, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 18, 2008

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2009

Completed
Last Updated

July 12, 2011

Status Verified

July 1, 2011

Enrollment Period

7 months

First QC Date

December 16, 2008

Last Update Submit

July 10, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Wake After Sleep Onset (WASO) between treatment with standard APAP and APAP modified by the addition of the SensAwake™ modification

    1 Night

Secondary Outcomes (2)

  • Sleep Efficiency

    1 night

  • Percentage of Slow Wave Sleep

    1 night

Study Arms (2)

1

EXPERIMENTAL

Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled

Device: SleepStyle 200 Auto Series with SensAwake

2

ACTIVE COMPARATOR

Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled

Device: SleepStyle 200 Auto Series with out SensAwake

Interventions

Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled

1

Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled

2

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18-65 years with moderate-to-severe OSA (Apnea Hypopnea index equal to or greater than 15 per hour).
  • Epworth Sleepiness Scale (ESS) scores 0-15 inclusive (normal to moderately severe daytime sleepiness).
  • Fluency in both written and spoken English.
  • Do not have unstable psychiatric disease.
  • No other significant sleep disorder.

You may not qualify if:

  • Participants prescribed and fitted with any PAP device in the past 2 years.
  • Unstable cardiovascular disease (untreated or resistant hypertension acceptable).
  • Inability to tolerate CPAP due to nasal obstruction or claustrophobia as determined by the study investigator.
  • Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as psychiatric disease, history of non compliance to medical regimens, or unwillingness to comply with study requirements.
  • Participation in another clinical trial in the previous month.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Woolcock Institute of Medical Research

Sydney, New South Wales, 2037, Australia

Location

Related Publications (1)

  • Dungan GC 2nd, Marshall NS, Hoyos CM, Yee BJ, Grunstein RR. A randomized crossover trial of the effect of a novel method of pressure control (SensAwake) in automatic continuous positive airway pressure therapy to treat sleep disordered breathing. J Clin Sleep Med. 2011 Jun 15;7(3):261-7. doi: 10.5664/JCSM.1066.

Related Links

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

  • Brendon Yee, MBChB

    Woolcock Institute of Medical Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

December 16, 2008

First Posted

December 18, 2008

Study Start

October 1, 2008

Primary Completion

May 1, 2009

Study Completion

August 1, 2009

Last Updated

July 12, 2011

Record last verified: 2011-07

Locations